MDM2 and mesothelioma: Treatment with LBH589, in MDM2-amplified and/or p53-mutant cell lines (LPS141, LPS141/239, LPS141/266, LPS510, LPS778, and JMN1B), had greater inhibitory effects on viability than in normal MDM2 and p53-wild-type cell lines MESO924 and MESO296, whereas the anti-proliferative effects of HDAC inhibition by SAHA in p53-wild-type mesothelioma cell lines were greater (MESO924 and MESO296) than LPS cell lines (Figure 3C).